路优泰与丁螺环酮治疗精神分裂症后焦虑的疗效观察  

Observation of the Efficacy of Neurostan and Buspirone in Treating Anxiety among Schizophrenia Patients

作　　者：姚丰菊[1] 李艳芬[1] 薛殿凯[1] 

机构地区：[1]新乡医学院第二附属医院,河南省新乡市453002

出　　处：《职业与健康》2006年第19期1628-1629,共2页Occupation and Health

摘　　要：目的了解路优泰对精神分裂症后焦虑的疗效。方法对53例精神分裂症后伴随焦虑症状患者采用单盲对照研究,使用汉密顿焦虑量表(HAMA)、药物副反应量表(TESS)、临床疗效总评量表(CGI)比较路优泰与丁螺环酮对精神分裂症后焦虑症状疗效,结果路优泰治疗组、丁螺环酮治疗组HAMA评分治疗后均比治疗前显著下降(P<0.01),但路优泰耐受性强于丁螺环酮,TESS分别为0.54±0.02和3.41±0.49,二者差异有非常显著性(P<0.01)。结论路优泰与丁螺环酮疗效相当,但不良反应少,安全性占优势。[Objective]To understand the efficacy of Neurostan in treating anxiety among schizophrenia patients. [Methods]Single - blind contrast study was carried out on 53 schizophrenia patients with anxiety; HAMA, TESS AND CGL was applied to compare the efficacy of Neurostan and Buspirone in treating anxiety among schizophrenia patients. [ Results] The HAMA grades of both Neurostan group and Buspirone group declined significantly after treatment （ P 〈 0.01 ）. But the tolerance in patients of Neurostan group was better than that of the Buspirone group; TESS of the two groups was 0.54 ± 0.02 and 3.41 ± 0.49 respectively, the difference was significant （ P 〈 0.01 ）. [Conclusion] Neurostan has similar efficacy with Buspirone but less side effects and stronger safety.

关 键 词：路优泰 丁螺环酮 精神分裂症后焦虑 

分 类 号：R759.3[医药卫生—皮肤病学与性病学]